U.S. Department of Health and Human Services
Prescription Drugs & Other Medical Products
Drugs and other medical products greatly impact human health and the health care system. ASPE conducts a variety of research in this area, including work related to medical product development and regulation; medical product markets, pricing and competition; prescription drug benefits and spending on medical products; medical product supply chains; and medical product safety.
Noteworthy
Reports
Displaying 131 - 140 of 177. 10 per page. Page 14.
Advanced SearchState Purchasing Strategies Drive State Contracts with Medicare Special Needs Plans
U.S. Department of Health and Human Services
Payment for Medicare Advantage Plans: Policy Issues and Options
Medicare Advantage (MA) is the current program under which beneficiaries can enroll in private health plans rather than having their care covered through Medicare's traditional fee for service (FFS) program. Payments to MA plans in many areas are now substantially greater than the cost of treating comparable beneficiaries in the traditional program.
Federal Authority for Medicare Special Needs Plans and their Relationship to State Medicaid Programs
This Brief reviews the history and current status of federal special needs plans (SNPs) authority, with particular attention to provisions of interest to state Medicaid programs that have or are considering entering into contracts with SNPs to integrate or coordinate Medicaid long-term care services with Medicare primary, acute and prescription drug services for dually eligible beneficiaries.
A Framework for Evaluating Quality Transparency Initiatives in Health Care
To date a number of private and public sector initiatives have commenced that rely on value-driven principles for the delivery of health care services. Given the variation that may exist across these initiatives it is important to have a good structure for examining and evaluating their implementation and overall effectiveness.
A Framework for Evaluating Price Transparency Initiatives in Health Care
To date a number of private and public sector initiatives have commenced that rely on value-driven principles for the delivery of health care services. Given the variation that may exist across these initiatives it is important to have a good structure for examining and evaluating their implementation and overall effectiveness.
Prescription Drug Spending by Medicare Beneficiaries in Institutional and Residential Settings, 1998-2001
U.S. Department of Health and Human Services
Drug Use and Spending for Medicare Beneficiaries During Part A Qualifying Skilled Nursing Facility Stays and Non-Qualifying Long-Term Care Facility Stays
This Policy Brief helps fill an important gap in our understanding of medication patterns in long-term care facilities (LTCFs) by comparing use and spending for prescription and over-the-counter drugs during skilled nursing facility (SNF) stays and related non-qualifying long-term care facility episodes.
A National Comparison of Prescription Drug Expenditures by Medicare Beneficiaries Living in the Community and Long-Term Care Facility Settings
This Policy Brief provides a snapshot of prescription drug use and spending in 2001, the latest year for which complete community and long-term care facility drug data are available.
Analysis of Supply, Distribution, Demand, and Access Issues Associated with Immune Globulin Intravenous (IGIV)
Contents IGIV Supply and Distribution - Key Findings IGIV Demand - Key Fundings IGIV Access Problems- Key Fundings Immune globulin intravenous (IGIV), also referred to as intravenous immune globulin (IVIG), is a valuable treatment for many seriously ill patients. Although the U.S.